Journal of Clinical Oncology
Articles in this Issue
Diagnostic performance of <sup>18</sup> F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc analysis from the phase 3 LIGHTHOUSE study.
311 Background: 18 F-Flotufolastat is a prostate-specific membrane antigen (PSMA)-targeting PET radiop...
Examination of Decipher prostate genomic classifier in patients with de novo metastatic disease from a large scale real-world clinical and transcriptomic data linkage.
224 Background: Prognostic gene expression testing of primary tumor tissue has become widely adopted for localized prostat...
A study of GSK5458514 administered alone or in combination with other anticancer agents in patients with prostate cancer.
TPS285 Background: Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer-related d...
Phase 1b/2 KEYMAKER-U03 substudy 03C of belzutifan plus zanzalintinib or belzutifan monotherapy for recurrent clear cell renal cell carcinoma during or after anti–PD-(L)1 therapy.
TPS579 Background: Adjuvant pembrolizumab is a standard of care for patients with renal cell carcinoma (RCC) at intermedia...
Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (OS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) and frailty or comorbidities.
666 Background: Enfortumab vedotin + pembrolizumab (EV+P) is now the preferred 1L tx for la/mUC, showing superior OS vs pl...
Real-world efficacy and safety of tivozanib in metastatic renal cell carcinoma in a diverse cohort: A multicenter study from the City of Hope enterprise.
477 Background: Tivozanib is a selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TK...
Effect of enzalutamide and bipolar androgen therapy on clonal hematopoiesis and clinical outcomes among men with metastatic castration resistant prostate cancer.
229 Background: Clonal hematopoiesis (CH) is frequently found in men with advanced prostate cancer and is associated with...
Digital monitoring of self-reported symptoms by patients treated with cabozantinib plus nivolumab for advanced clear-cell renal carcinoma (CANIQOL).
TPS570 Background: Cabozantinib plus nivolumab is a first-line standard treatment for advanced clear-cell renal cell carci...
Use of genomic dedifferentiation signature to predict clinical outcomes with doublet vs triplet therapy in the phase III COSMIC-313 trial.
523 Background: The Genomic Dedifferentiation Signature (GDS) has previously been shown to differentiate clinical outcomes...
Urologist-level variation in androgen deprivation therapy intensification in patients with metastatic hormone-sensitive prostate cancer: A retrospective, population-based cohort study in Ontario, Canada.
59 Background: Guidelines recommend androgen-deprivation therapy (ADT) intensification for individuals with de novo metast...
Epigenomic alterations associated with androgen receptor pathway inhibitor response in metastatic castration-resistant prostate cancer.
220 Background: Androgen receptor pathway inhibitors (ARPIs) improve survival in patients with metastatic castration-resis...
Patient and physician preferences for treatment in advanced renal cell carcinoma (PEAR): An international, multi-centre discrete choice experiment (DCE).
443 Background: There are several treatment options for advanced renal cell carcinoma (aRCC) but limited evidence for trea...
Patient-reported outcomes in resected renal cell carcinoma: Active monitoring vs. durvalumab and tremelimumab in the RAMPART trial.
420 Background: Durvalumab + Tremelimumab (DT) given over one year (with Tremelimumab at Day 1 and Week 4), improved disea...
Real-world (rw) safety of first-line (1L) systemic regimens for locally advanced or metastatic urothelial cancer (la/mUC): Updated results from the ELEVATE UC-I study.
680 Background: The rw safety of contemporary 1L treatment (tx) regimens for la/mUC has been previously reported. This upd...
Systemic therapy combined with radiotherapy versus systemic therapy alone for oligometastatic kidney cancer (STROKER): A multicenter, randomized controlled phase III trial.
TPS576 Background: The value of local therapy for oligometastatic renal cell carcinoma (RCC) remains undefined. Several si...
A phase II trial of cabozantinib in relapsed refractory germ-cell tumors (GCT).
587 Background: Vascular endothelial growth factor overexpression, increased angiogenesis, and activation of the c-MET pat...
Single-cell transcriptomic characterization of NECTIN-4 expression in penile squamous cell carcinoma.
9 Background: NECTIN-4, a cell adhesion molecule and target of the antibody–drug conjugate enfortumab vedotin, has emerged...
Impact of age on outcomes in metastatic non–clear cell renal cell carcinoma (mnccRCC): A real-world TriNetX analysis.
453 Background: Malignancies arising in young adults often exhibit biological and clinical behaviors distinct from those i...
The ITALIC-RCC study: A randomized study of clinical and humoral impact of primary tumor ablation in metastatic renal cell carcinoma treated with immunotherapy.
TPS584 Background: The role and optimal timing of cytoreductive nephrectomy (CN) have long been subject of debate in the m...
Improving delivery of prostate cancer germline testing at the Department of Veterans Affairs: A cluster-randomized trial.
TPS270 Background: ~15,000 men with metastatic prostate cancer (MPCa) receiving care in the Veterans Administration (VA) c...
A binary dual-stain immunohistochemistry classifier to predict pathologic downstaging after neoadjuvant chemotherapy in muscle-invasive bladder cancer.
842 Background: Luminal and basal bladder cancers exhibit differential chemosensitivity, yet intratumoral heterogeneity li...
Prospective, blinded validation of a urinary cfDNA methylation assay in bladder cancer.
820 Background: Cystoscopy is the standard for local bladder cancer (BC) detection and follow-up, but is invasive and cost...
Internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors: The iLIVE trial.
TPS274 Background: Obese frailty is a growing national problem as trends towards aging and obesity converge. This problem...
Benign persistent elevation of alphafoetoprotein (AFP) after curative treatment for germ-cell tumors.
598 Background: Follow-up of patients with germ-cell tumours (GCT) relies on monitoring serum markers (SM) including alpha...
Is it time to redefine the Phoenix criterion for biochemical failure in the era of PSMA PET/CT?
319 Background: Biochemical recurrence (BCR) of prostate cancer (PCa) is traditionally defined by the Phoenix criterion (P...